<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19763">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02849613</url>
  </required_header>
  <id_info>
    <org_study_id>38RC15.337</org_study_id>
    <nct_id>NCT02849613</nct_id>
  </id_info>
  <brief_title>Regenerative Stem Cell Therapy for Stroke in Europe</brief_title>
  <acronym>RESSTORE</acronym>
  <official_title>Regenerative Stem Cell Therapy for Stroke in Europe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission H2020 program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Univ Grenoble Alpes, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Servicio Madrileño de Salud, Madrid, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fakultni Nemocnice U Sv. Anny v Brne, Brno, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Servicio Andaluz de Salud, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Glasgow</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Eastern Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Etablissement Français du Sang</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Tampere</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Histocell SL, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medfiles CRO, Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Association groupe ESSEC, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NOVADISCOVERY SAS, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>FINOVATIS, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHU Besancon, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHU Toulouse, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHU Bordeaux, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHU Cote de Nacre, Caen, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Servicio de Salud de Castilla La Mancha, Albacete, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Servizo Galego de Saude, Santiago de Compostela, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pirkanmaa Hospital District, Tampere, Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Vall d'Hebron</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stroke is the second leading cause of death in the world population. When not fatal, stroke
      often results in disability, and secondary health problems affecting not only patients but
      also their families. Building on emerging preclinical and pilot clinical evidences, RESSTORE
      will focus on the clinical assessment of regenerative cell therapy to improve stroke
      recovery and patients quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RESSTORE European multicentre randomised phase IIb will explore the efficacy (functional
      recovery) and safety of intravenous infusion of allogenic adipose tissue derived mesenchymal
      stem cells (ADSC) in 400 stroke patients. Therapeutic effects of ADSCs will be assessed and
      monitored in patients using clinical rating scales, multimodal MRI and blood biomarkers.

      The European regenerative therapy capacities (France, Spain, Finland, United Kingdom and
      Czech Republic), developed in RESSTORE will cover the full value chain in the field (large
      scale GMP cell production, clinical testing, biomarkers discovery, understanding of the
      restoring mechanisms, biobanking...).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Between-group difference of NIHSS (stroke severity score)</measure>
    <time_frame>6 months after stroke onset</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Adipose derived Stem Cells ADSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADSC, single IV, 1.106 cells/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle media</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>IV infusion of cell excipients, 1ml/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Adipose Derived Stem Cells</intervention_name>
    <arm_group_label>Adipose derived Stem Cells ADSC</arm_group_label>
    <other_name>ADSC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle media</intervention_name>
    <arm_group_label>Vehicle media</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hemispheric ischemic stroke (&gt;1.5cm)

          -  Inclusion from 1 to 4 days post-stroke

          -  NIHSS &gt; or = 7

          -  No craniectomy

          -  Able to follow a rehabilitation program

          -  Modified Rankin scale = 0 before stroke onset

        Exclusion Criteria:

          -  Coma

          -  Severe leucoariosis

          -  Previous stroke

          -  Active endocarditis, pneumonia, AIDS, active hepatic disease due to HBV or HCV

          -  History of cancer

          -  Pregnancy, breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier DETANTE, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Grenoble-Alpes, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Exuperio DIEZ TEJEDOR, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>La Paz University Hospital, Madrid, Spain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claire BOLLART</last_name>
    <phone>(0)4 76 76 59 57</phone>
    <phone_ext>+33</phone_ext>
    <email>ArcPromoteur@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laetitia WIOLAND, PhD</last_name>
    <phone>(0)4 76 76 57 89</phone>
    <phone_ext>+33</phone_ext>
    <email>laetitia.wioland@univ-grenoble-alpes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Grenoble Hospital / EFS</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier DETANTE, MD PhD</last_name>
      <phone>(0)4 76 76 57 89</phone>
      <phone_ext>+33</phone_ext>
      <email>ODetante@chu-grenoble.fr</email>
    </contact>
    <contact_backup>
      <last_name>Laetitia WIOLAND, PhD</last_name>
      <phone>(0)4 76 76 57 89</phone>
      <phone_ext>+33</phone_ext>
      <email>laetitia.wioland@univ-grenoble-alpes.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.resstore.eu/</url>
    <description>Website</description>
  </link>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 26, 2016</lastchanged_date>
  <firstreceived_date>July 6, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cell therapy</keyword>
  <keyword>stem cell</keyword>
  <keyword>transplantation</keyword>
  <keyword>graft</keyword>
  <keyword>recovery</keyword>
  <keyword>repair</keyword>
  <keyword>stroke</keyword>
  <keyword>mesenchymal stem cell</keyword>
  <keyword>regenerative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
